CRA Handbook 2014; Electronic Edition
Table of Contents [00] Foreword [01] CFR Part 812—Investigational Device Exemptions [02] CFR Part 814.20—Premarket Approval Applications [03] CFR Part 11—Electronic Records; Electronic Signatures [04] CFR Part 50—Protection of Human Subjects [05] CFR Part 54—Financial Disclosure [06] CFR Part 56—Institutional Review Boards [07] CFR Part 99—Dissemination of Information [08] CFR Part 809—In Vitro Diagnostic Products [09] CFR Part 820.30—Quality System—Design Controls [10] Expedited Review List [11] Risk-Based Monitoring—The New FDA Guidance [12] Monitoring Task Lists and Documentation Checklists [13] Declaration of Helsinki (2013) [14] ISO 14155 (2011) Summary [15] Adverse Events & Effects [16] FDA Guidance List Table of Figures and Tables [Figure 1] Flowchart for IDEs [Table 2] Comparison of IDE Requirements [Figure 3] Oral Informed Consent [Figure 4] Financial Disclosure by Investigators [Figure 5] Overview of the Monitoring Process Task Lists: [Table 6] Prestudy Visit [Table 7] Study Initiation Visit [Table 8] Routine Monitoring Visit [Table 9] Study Close-out Document Checklists:
[Figure 15] Device Design Process in the EU
|